AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2185042 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed intercourse with clomiphene citrate (CC)
Number of subjects: 40
Study 2185042 — intervention group
Group type: COMPARATOR
Intervention: Timed intercourse with spontaneous cycles
Number of subjects: 40
Study 74317 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (1 g/kg)
Number of subjects: 9
Study 74317 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol plus pyrithioxine (7 mg/kg)
Number of subjects: 9
Study 74317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrithioxine (7 mg/kg) plus alcohol
Number of subjects: 9
Study 74317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31430183 — intervention group
Group type: EXPERIMENTAL
Intervention: 290-NBI
Number of subjects: 117
Study 31430183 — intervention group
Group type: COMPARATOR
Intervention: HDWL
Number of subjects: 117
Study 30234616 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum MIYAIRI 588 (CBM588) 60 mg/d in combination with antidepressants
Number of subjects: 40
Study 30234616 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 40
Study 26723854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 30
Study 26723854 — intervention group
Group type: COMPARATOR
Intervention: Conventional stroke rehabilitation program
Number of subjects: 30
Study 24156501 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripts depicting efforts by a middle-aged daughter to raise the topic of future care needs with her mother by implementing a variety of facework behaviors
Number of subjects: 130
Study 24156501 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripts with varying degrees of respect for mother's autonomy and connection
Number of subjects: 130
Study 22376375 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECT + FALLS
Number of subjects: 16
Study 22376375 — intervention group
Group type: COMPARATOR
Intervention: FALLS
Number of subjects: 16
Study 20621945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention Group (CIG)
Number of subjects: 40
Study 20621945 — intervention group
Group type: COMPARATOR
Intervention: Placebo Group
Number of subjects: 40
Study 20621945 — intervention group
Group type: COMPARATOR
Intervention: Untreated Group
Number of subjects: 40
Study 18158814 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 75
Study 18158814 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mcg/kg granisetron
Number of subjects: 75
Study 18158814 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mcg/kg ondansetron
Number of subjects: 75
Study 16338566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral blue light-filtering intraocular lens (IOL)
Number of subjects: 0
Study 16338566 — intervention group
Group type: COMPARATOR
Intervention: Similar IOL that does not filter blue light
Number of subjects: 0
Study 16325621 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for stress incontinence
Number of subjects: 650
Study 11491155 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg)
Number of subjects: 16
Study 11491155 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium (36 microg)
Number of subjects: 16
Study 9565268 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration with resorbable membrane (n=10)
Number of subjects: 30
Study 9565268 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration with nonresorbable membrane (n=10)
Number of subjects: 30
Study 9565268 — intervention group
Group type: COMPARATOR
Intervention: Control group treated by enucleation and primary closure (n=10)
Number of subjects: 30
Study 7840721 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 36
Study 7840721 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 36
Study 7840721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3048216 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial dermis
Number of subjects: 106
Study 3048216 — intervention group
Group type: COMPARATOR
Intervention: Control (investigator's usual skin grafting material)
Number of subjects: 106
Study 3048216 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 106
Study 29882073 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-monthly (PP3M)
Number of subjects: 1161
Study 29882073 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-monthly (PP1M)
Number of subjects: 1161
Study 28470156 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Program (RPP), 3 one-hour sessions over 10 days prior to discharge
Number of subjects: 54
Study 28470156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RPP)
Number of subjects: 54
Study 25040766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite oral rinse (15 mL, twice a week for 3 months)
Number of subjects: 12
Study 25040766 — intervention group
Group type: COMPARATOR
Intervention: Water rinse (control group)
Number of subjects: 12
Study 25040766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite oral rinse
Number of subjects: 12
Study 23276660 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 250μg
Number of subjects: 62
Study 23276660 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 500μg
Number of subjects: 62
Study 23276660 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 1000μg
Number of subjects: 62
Study 23276660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide 18μg
Number of subjects: 62
Study 23276660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 23276660 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 250μg (repeat dose)
Number of subjects: 62
Study 23276660 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium 1000μg (repeat dose)
Number of subjects: 62
Study 23276660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (repeat dose)
Number of subjects: 62
Study 20738470 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (feedback + health letter)
Number of subjects: 105
Study 20738470 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (health letter only)
Number of subjects: 105
Study 20738470 — intervention group
Group type: COMPARATOR
Intervention: Group C (control group)
Number of subjects: 105
Study 17964576 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of 17-beta estradiol orally for 1 month then 2 mg for 2 months
Number of subjects: 22
Study 17964576 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol treatment
Number of subjects: 22
Study 17964576 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 22
Study 17964576 — intervention group
Group type: COMPARATOR
Intervention: Antimuscarinic drug scopolamine (SCOP)
Number of subjects: 22
Study 17964576 — intervention group
Group type: COMPARATOR
Intervention: Antinicotinic drug mecamylamine (MECA)
Number of subjects: 22
Study 16569537 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril (2 mg/d)
Number of subjects: 24
Study 16569537 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/d)
Number of subjects: 24
Study 16569537 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 12749831 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 23
Study 12749831 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 23
Study 12749831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11135211 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m(2) and cyclophosphamide 600 mg/m(2) intravenously every 3 weeks (AC)
Number of subjects: 124
Study 11135211 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 100 mg/m(2) orally on Days 1-14, methotrexate 40 mg/m(2) and 5-fluorouracil 500 mg/m(2) intravenously on Days 1 and 8 every 4 weeks (CMF)
Number of subjects: 124
Study 11135211 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC)
Number of subjects: 124
Study 11135211 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
Number of subjects: 124
Study 11135211 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 124
Study 9370408 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cold blood cardioplegia (RCBC)
Number of subjects: 158
Study 9370408 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cold blood cardioplegia (ACBC)
Number of subjects: 158
Study 9370408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study 1437685 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilled composite resin
Number of subjects: 0
Study 1437685 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured glass-ionomer liner and microfilled resin (sandwich technique)
Number of subjects: 0
Study 1437685 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured glass-ionomer liner only
Number of subjects: 0
Study 3932509 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diet supplemented with 2000 kCal and 10 g nitrogen daily (branched chain amino acid enriched formulation)
Number of subjects: 64
Study 3932509 — intervention group
Group type: COMPARATOR
Intervention: Controlled diet alone (Control)
Number of subjects: 64
Study 3932509 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented groups (branched chain amino acids)
Number of subjects: 64
Study 3932509 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral or parenteral branched chain amino acids
Number of subjects: 64
Study 31229634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 71
Study 31229634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 71
Study 28372849 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate drink (8.5 g before breakfast and 8.5 g before dinner)
Number of subjects: 26
Study 28372849 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (identical in appearance and taste, lacking carbohydrate, fat or protein)
Number of subjects: 26
Study 28372849 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate drink
Number of subjects: 26
Study 26872077 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 199
Study 26872077 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 199
Study 24215127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab (0.5 mg)
Number of subjects: 39
Study 24215127 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy subjects)
Number of subjects: 39
Study 22409311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic strategy training
Number of subjects: 49
Study 22409311 — intervention group
Group type: COMPARATOR
Intervention: Matched exposure control
Number of subjects: 49
Study 19756418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin once daily (treatment B)
Number of subjects: 30
Study 19756418 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin thrice daily (treatment A)
Number of subjects: 30
Study 19756418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study 17605571 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention prompt
Number of subjects: 55
Study 17605571 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 55
Study 15837983 — intervention group
Group type: COMPARATOR
Intervention: FEC 50 (fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 50 mg/m2)
Number of subjects: 565
Study 15837983 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 100 (fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2)
Number of subjects: 565
Study 12901530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% tetracaine
Number of subjects: 43
Study 12901530 — intervention group
Group type: COMPARATOR
Intervention: 0.3% ropivacaine
Number of subjects: 43
Study 9878641 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin (300 mg, twice daily for four weeks)
Number of subjects: 520
Study 9878641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 8924741 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched enteral diet (n=26)
Number of subjects: 77
Study 8924741 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formula (n=24)
Number of subjects: 77
Study 8924741 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (n=27)
Number of subjects: 77
Study 1851577 — intervention group
Group type: COMPARATOR
Intervention: lonidamine (A)
Number of subjects: 184
Study 1851577 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin‐C/vindesine (B)
Number of subjects: 184
Study 1851577 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin‐C/vindesine plus lonidamine (C)
Number of subjects: 184
Study 7152080 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprosalic lotion (betamethasone dipropionate and salicylic acid)
Number of subjects: 51
Study 7152080 — intervention group
Group type: COMPARATOR
Intervention: Dermovate lotion (clobetasol propionate)
Number of subjects: 51
Study 7152080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 51
Study 6317816 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal lecture (auditory, visual, and tactile senses)
Number of subjects: 43
Study 6317816 — intervention group
Group type: COMPARATOR
Intervention: Formal lecture (auditory sense only)
Number of subjects: 43
Study 31293199 — intervention group
Group type: EXPERIMENTAL
Intervention: W-GEE (weighted generalized estimating equation)
Number of subjects: 0
Study 31293199 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI-GEE (multilevel multiple imputation for GEE)
Number of subjects: 0
Study 31293199 — intervention group
Group type: EXPERIMENTAL
Intervention: CW-GEE (clustering weighted generalized estimating equation)
Number of subjects: 0
Study 31293199 — intervention group
Group type: COMPARATOR
Intervention: W-GEE
Number of subjects: 0
Study 28817231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 28817231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0
Study 28817231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg and 0.75 mg
Number of subjects: 0
Study 27981279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular platelet-rich plasma (PRP) (3 ml)
Number of subjects: 43
Study 27981279 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular hyaluronic acid (HA) (30 mg/2 ml; 1,000-2,900 kDa)
Number of subjects: 43
Study 25549681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioscorea modified pill
Number of subjects: 100
Study 25549681 — intervention group
Group type: COMPARATOR
Intervention: Aricept
Number of subjects: 100
Study 22734375 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nursing group (n=248)
Number of subjects: 372
Study 22734375 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing group (n=124)
Number of subjects: 372
Study 19620184 — intervention group
Group type: EXPERIMENTAL
Intervention: K-wire group (n = 30)
Number of subjects: 60
Study 19620184 — intervention group
Group type: COMPARATOR
Intervention: Cast group (n = 30)
Number of subjects: 60
Study 19620184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study 18242485 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (140 microg/kg/min)
Number of subjects: 54
Study 15606446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 13
Study 15606446 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 13
Study 15606446 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 13
Study 11496732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiklid
Number of subjects: 0
Study 11496732 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 11496732 — intervention group
Group type: COMPARATOR
Intervention: ADP, PHA-P, WGA, Con A
Number of subjects: 0
Study 9781802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral IFN-alpha (200 IU daily sublingual dose)
Number of subjects: 30
Study 7828634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously injected hyaluronan (HA)
Number of subjects: 12
Study 3418660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure at P6 (Neiguan) acupuncture point
Number of subjects: 350
Study 3418660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure at a point near the right elbow (dummy pressure)
Number of subjects: 350
Study 3418660 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 350
Study 31784929 — intervention group
Group type: EXPERIMENTAL
Intervention: PhotoBioModulation (PBM)
Number of subjects: 20
Study 31784929 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 20
Study 30285647 — intervention group
Group type: COMPARATOR
Intervention: Exposure to stressful life events (father's alcoholism)
Number of subjects: 1796
Study 30285647 — intervention group
Group type: COMPARATOR
Intervention: Exposure to stressful life events (severe illness of a close family member)
Number of subjects: 1796
Study 30285647 — intervention group
Group type: COMPARATOR
Intervention: Exposure to stressful life events (hospitalization of the child for another illness)
Number of subjects: 1796
Study 30285647 — intervention group
Group type: COMPARATOR
Intervention: Exposure to stressful life events (being bullied at school)
Number of subjects: 1796
Study 30285647 — intervention group
Group type: COMPARATOR
Intervention: Exposure to stressful life events (loss of a parent's job)
Number of subjects: 1796
Study 30285647 — intervention group
Group type: COMPARATOR
Intervention: Symptoms associated with constipation (abdominal pain)
Number of subjects: 1796
Study 30285647 — intervention group
Group type: COMPARATOR
Intervention: Symptoms associated with constipation (straining)
Number of subjects: 1796
Study 26173463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant fixed partial prostheses (IFPP)
Number of subjects: 48
Study 26173463 — intervention group
Group type: COMPARATOR
Intervention: Mandibular implant-supported overdenture (ISOD)
Number of subjects: 48
Study 23300117 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 1081
Study 23300117 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 1081
Study 23300117 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 1081
Study 23300117 — intervention group
Group type: COMPARATOR
Intervention: MTX-only
Number of subjects: 1081
Study 23300117 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 1081
Study 22386826 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg commercial sildenafil (reference)
Number of subjects: 0
Study 22386826 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg generic sildenafil (test 1)
Number of subjects: 0
Study 22386826 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg chewable generic sildenafil (test 2)
Number of subjects: 0
Study 22386826 — intervention group
Group type: COMPARATOR
Intervention: Tolerability assessment
Number of subjects: 0
Study 19656218 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional clamp with immediate post-pressing time for conventional heat-cure resin
Number of subjects: 0
Study 19656218 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional clamp with 6-h post-pressing time for conventional heat-cure resin
Number of subjects: 0
Study 19656218 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post-pressing time for conventional heat-cure resin
Number of subjects: 0
Study 19656218 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-h delay in post-pressing time for rapid cycle heat-cure resin
Number of subjects: 0
Study 18036005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 18036005 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee group
Number of subjects: 113
Study 18036005 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist group
Number of subjects: 113
Study 18036005 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 113
Study 18036005 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurses
Number of subjects: 113
Study 16195581 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermented with Lactobacillus acidophilus strain L-92 (L-92), 100 ml, containing 5 x 10(10) bacteria, twice a day for 6 weeks
Number of subjects: 23
Study 16195581 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermented with Lactobacillus acidophilus strain L-92 (L-92), daily dose of 2 x 10(10) bacteria for 10 weeks
Number of subjects: 23
Study 16195581 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 23
Study 12192847 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A dressing
Number of subjects: 200
Study 12192847 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B dressing
Number of subjects: 200
Study 12192847 — intervention group
Group type: EXPERIMENTAL
Intervention: Type C dressing
Number of subjects: 200
Study 9475563 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg inhaled at bedtime followed by unblinded salmeterol 50 microg inhaled 12 hours later
Number of subjects: 10
Study 9475563 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaled at bedtime followed by unblinded salmeterol 50 microg inhaled 12 hours later
Number of subjects: 10
Study 8713438 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (prophylactic)
Number of subjects: 29
Study 8713438 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (therapeutic)
Number of subjects: 29
Study 8713438 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 29